EliasIObeidMDMPH
Oncology • Philadelphia, PABreast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology
Assistant Professor
Dr. Obeid is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Departmet of Clinical Genetics
Philadelphia, PA 19111Phone+1 215-728-2791Fax+1 215-214-3779
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2009 - 2013
Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
American University of Beirut Faculty of MedicineClass of 2000
Certifications & Licensure
NJ State Medical License 2022 - 2025
PA State Medical License 2013 - 2024
IL State Medical License 2009 - 2014
CT State Medical License 2004 - 2010- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Start of enrollment: 2016 May 31
- A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Start of enrollment: 2020 Jun 10
Publications & Presentations
PubMed
- 6 citationsA phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.Matthew Zibelman, Alexander W MacFarlane 4th, Kimberly Costello, Thomas McGowan, John O'Neill
Nature Communications. 2023-07-27 - 155 citationsThe role of tumor-associated macrophages in breast cancer progression (Review)Elias Obeid, Rita Nanda, Yang Xin Fu, Olufunmilayo I. Olopade
International Journal of Oncology. 2013-07-01 - 98 citationsEarly onset HER2-positive breast cancer is associated with germline TP53 mutationsAmal Melhem-Bertrandt, Jasmina Bojadzieva, Kaylene Ready, Elias Obeid, Diane D. Liu
Cancer. 2012-02-15
Press Mentions
'Patients Are Going to Ask for It': Inside Ochsner's Pharmacogenomic Testing ProgramSeptember 9th, 2024- HMH, St. Joseph’s Open Cancer Center of TotowaMay 26th, 2023
- St. Joseph’s Health and Hackensack Meridian Health Open Comprehensive Cancer Center at TotowaMay 25th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
